

REMARKS

Applicants have amended FIGS. 23 and 24 to remove extraneous text from the legend and to remove the descriptive text below each graph. Applicants have amended the specification to add to the description of Figs. 23 and 24 the descriptive text that was removed from the drawing sheets containing Figs. 23 and 24. Applicants submit that these amendments introduce no new matter.

The Examiner is invited to contact the undersigned with any questions about this Amendment.

TRANSMITTAL OF FORMAL DRAWINGS


Enclosed please find 24 sheets of formal drawings corresponding to FIGS. 1-24 for the above-referenced patent application.

Respectfully submitted,

Date: August 9, 2004
Reg. No. 55,489

Tel. No.: (617) 310-8636
Fax No.: (617) 248-7100

3099634



Michael J. Nesler
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Annotated Sheet

Fig.: 22




Fig.: 23




Figure 23 shows the normalized absorption spectra of two streptavidin conjugates obtained by reacting DY-631-NHS esters or DY-630-NHS esters with streptavidin in the molar ratio of 2:1. The advantage of the new markers is very clearly apparent from the clearly reduced aggregation band for the DY-631 conjugate at 580 nm.

Annotated Sheet

Fig.: 24




Figure 24 shows the normalized absorption spectra of two streptavidin conjugates obtained by reacting DY-701-NHS esters or DY-700-NHS esters with streptavidine in the molar ratio of 2:1. The advantage of the new markers is very clearly apparent from the reduced aggregation band for the DY-701 conjugate at 650 nm.



Replacement Sheet

23/24




FIG. 23




FIG. 24